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A 37-year-old man was diagnosed with psoriasis and psoriatic
arthritis in February 2006. Previous treatment with sulfasalazine,
leﬂunomide, nonsteroidal anti-inﬂammatory drugs, etanercept,
and topical steroids showed limited effects. Adalimumab at
40 mg every 2 weeks was given since April 2013. His skin condi-
tion and arthritis improved during the treatment, with the Psori-
asis Area and Severity Index decreasing from 2.2 to 0.3 and
tender joint counts from 5 to 0. However, asymptomatic whitish
linear patches and pinpoint lichenoid papules were noted over
the right arm (Figure 1A) and shoulder area (Figure 1B) 3 months
later. According to the patient, mild erythema preceded the
appearance of the eruptions, and he denied viral infection or
local trauma history on the right upper extremity in recent 3
months. Laboratory data were all within normal limits and he
was otherwise healthy, without atopy history. A skin biopsy
showed psoriasiform hyperplasia with basal vacuolization and
pigment incontinence. Superﬁcial perivascular and perieccrine
lymphocytic inﬁltration was noted as well (Figure 1C and D).
Lichen striatus was diagnosed. Adalimumab was discontinued
since December 2013, owing to the improvement of psoriasis
and psoriatic arthritis. We followed this patient regularly, and
the linear skin lesions improved spontaneously. Figure 1E shows
the signiﬁcant improvement 6 months after the patient stopped
taking adalimumab.
Cutaneous eruptions have been increasingly reported after the
use of tumor necrosis factor (TNF) blockers, such as acneiform
eruption, alopecia areata, urticaria, and palisaded neutrophilic
and granulomatous dermatitis.1,2 Lichen striatus is an enigmatic
self-limiting inﬂammatory dermatosis with lesions following the
lines of Blaschko, particularly common in children. The etiology
of the eruption is unknown, but environmental factors, viral infec-
tion, cutaneous injury, hypersensitivity, and genetic predisposition
have been implicated. The differential diagnosis includes
epidermal nevi, linear psoriasis, linear morphea, linear lichen
planus, and linear cutaneous lupus erythematosus. Lichen striatus
typically presents as a nonpruritic continuous or interrupted linear
band of small (1e3 mm) pink or hypopigmented papules, with a
smooth surface or mild scaling. Histopathologic ﬁndings dependConﬂicts of interest: The authors declare that they have no ﬁnancial or non-ﬁnancial co
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lichenoid inﬂammation. Perivascular and deep lymphocytic inﬁl-
trate surrounding the hair follicles and eccrine glands are
characteristic.
Lichen striatus can be associated with psoriasis or eczema. In a
small case series of 18 patients with lichen striatus, Taieb et al3
described two patients with psoriasis and six patients with atopic
diathesis. Another three cases of psoriasis coexisting with lichen
striatus were also found in our literature search. In the ﬁrst case,
unilateral lichen striatus preceded unilateral eruptive psoriasis
on the contralateral side, and a common trigger was suspected
to be the cause.4 In the second case report, lichen striatus devel-
oped in a patient with chronic plaque psoriasis after ultraviolet
phototherapy. However, the authors thought that phototherapy
did not cause lichen striatus, because lichen striatus resolved
despite continuous phototherapy.5 In the third case, lichen striatus
occurred after adalimumab treatment in a patient with long-
standing psoriasis.6 The extent of the eruption was more extensive
than in our case, but both occurred 3 months after adalimumab
treatment.
The mechanism of this unique phenomenon is unknown. It
could be Th1/Th2 imbalance, cytokine imbalance between TNF-
alpha and interferon-alpha, or loss of immune tolerance induced
by an acquired stimulus, after TNF blockers.7,8 Lichen striatus asso-
ciated with etanercept therapy in rheumatoid arthritis was re-
ported recently.9 In our case, however, lichen striatus did not
happen during the course of etanercept treatment. Although both
are TNF blockers, etanercept and adalimumab still differ in terms
of the mode of action.10 We speculate that the difference in the de-
gree of immunosuppression may be one reason. Adalimumab is
considered more immunosuppressive because clinical improve-
ment of psoriasis is higher after adalimumab compared to etaner-
cept. In addition, infection rate (in particular, tuberculosis) is also
higher for adalimumab compared to etanercept. In our previous
report, maximal improvement of psoriasis occurred 3 months after
adalimumab treatment, coincidental with the time of onset of
lichen striatus in our case.11
In summary, we report a patient with psoriasis who developed
lichen striatus after adalimumab treatment. Although coincidence
cannot be ruled out, we propose that lichen striatus should benﬂicts of interest related to the subject matter or materials discussed in this article.
ier Taiwan LLC. All rights reserved.
Figure 1 (A) Whitish linear patches over the right arm, following the lines of Blaschko. (B) Hypopigmented pinpoint lichenoid papules on the right shoulder. (C) Superﬁcial peri-
vascular and perieccrine lymphocytic inﬁltration (H&E). (D) Higher power ﬁeld showed perieccrine lymphocytic inﬁltration (H&E). (E) Follow-up picture 6 months after discontin-
uing adalimumab treatment. H&E ¼ hematoxylin and eosin.
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